1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Correction: Faria, A.V.S. et al., Targeting Tyrosine Phosphatases by 3-Bromopyruvate Overcomes Hyperactivation of Platelets from Gastrointestinal Cancer Patients. J. Clin. Med. 2019, 8, 936

      correction

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The authors wish to make the following correction to their paper [1], published on 28 June 2019 in Journal of Clinical Medicine. Figure 1A in the published version is incorrect due to the authors’ carelessness. The authors sincerely apologize for this mistake to all the readers. The journal office has checked the review history and found all drafts of the article used the correct picture for Figure 1A apart from the final publication version. Thus, this correction does not alter the interpretation or conclusions drawn from the present study. Figure 1 should be replaced with the following, correct picture: The published version will be updated online on the article webpage, with a reference to this correction.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Targeting Tyrosine Phosphatases by 3-Bromopyruvate Overcomes Hyperactivation of Platelets from Gastrointestinal Cancer Patients

          Venous thromboembolism (VTE) is one of the most common causes of cancer related mortality. It has been speculated that hypercoagulation in cancer patients is triggered by direct or indirect contact of platelets with tumor cells, however the underlying molecular mechanisms involved are currently unknown. Unraveling these mechanisms may provide potential avenues for preventing platelet-tumor cell aggregation. Here, we investigated the role of protein tyrosine phosphatases in the functionality of platelets in both healthy individuals and patients with gastrointestinal cancer, and determined their use as a target to inhibit platelet hyperactivity. This is the first study to demonstrate that platelet agonists selectively activate low molecular weight protein tyrosine phosphatase (LMWPTP) and PTP1B, resulting in activation of Src, a tyrosine kinase known to contribute to several platelet functions. Furthermore, we demonstrate that these phosphatases are a target for 3-bromopyruvate (3-BP), a lactic acid analog currently investigated for its use in the treatment of various metabolic tumors. Our data indicate that 3-BP reduces Src activity, platelet aggregation, expression of platelet activation makers and platelet-tumor cell interaction. Thus, in addition to its anti-carcinogenic effects, 3-BP may also be effective in preventing platelet-tumor cell aggregationin cancer patients and therefore may reduce cancer mortality by limiting VTE in patients.
            Bookmark

            Author and article information

            Journal
            J Clin Med
            J Clin Med
            jcm
            Journal of Clinical Medicine
            MDPI
            2077-0383
            13 August 2020
            August 2020
            13 August 2020
            : 9
            : 8
            : 2625
            Affiliations
            [1 ]Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, NL-3000 CA Rotterdam, The Netherlands; alessandravsfaria@ 123456gmail.com (A.V.S.F.); a.reijm@ 123456erasmusmc.nl (A.N.R.); v.spaander@ 123456erasmusmc.nl (M.C.W.S.); m.peppelenbosch@ 123456erasmusmc.nl (M.P.P.)
            [2 ]Department of Biochemistry and Tissue Biology, University of Campinas, UNICAMP, Campinas, SP 13083-862, Brazil
            [3 ]PlateInnove Biotechnology, Piracicaba, SP 13414-018, Brazil; sheilasa@ 123456gmail.com
            [4 ]Department of Hematology, Erasmus University Medical Center Rotterdam, NL-3000 CA Rotterdam, The Netherlands; m.demaat@ 123456erasmusmc.nl
            Author notes
            [* ]Correspondence: carmenv@ 123456unicamp.br (C.V.F.-H.); g.fuhler@ 123456erasmusmc.nl (G.M.F.); Tel.: +55-(19)-3521-6659 (C.V.F.-H.); +31-(0)107032759 (G.M.F.)
            Author information
            https://orcid.org/0000-0003-1161-5724
            https://orcid.org/0000-0001-5524-1360
            https://orcid.org/0000-0002-9103-9757
            https://orcid.org/0000-0001-7749-334X
            https://orcid.org/0000-0001-9112-6028
            https://orcid.org/0000-0001-9221-4855
            Article
            jcm-09-02625
            10.3390/jcm9082625
            7465274
            32823601
            e547d435-74f8-41c9-8457-99f6eeeb9f5a
            © 2020 by the authors.

            Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

            History
            : 30 July 2020
            : 07 August 2020
            Categories
            Correction

            Comments

            Comment on this article